EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.

doi:10.1097/JTO.0b013e31824a8bde

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2012

Milella Michele, Nuzzo Carmen, Bria Emilio, Sperduti Isabella, Visca Paolo, Buttitta Fiamma, Antoniani Barbara, Merola Roberta, Gelibter Alain, Cuppone Federica, D'Alicandro Valerio, Ceribelli Anna, Rinaldi Massimo, Cianciulli Anna, Felicioni Lara, Malatesta Sara, Marchetti Antonio, Mottolese Marcella, Cognetti Francesco

Abstract excerpt

INTRODUCTION: The optimal use of epidermal growth factor receptor (EGFR)-related molecular markers to prospectively identify tyrosine kinase inhibitor (TKI)-sensitive patients, particularly after a previous chemotherapy treatment, is currently under debate. METHODS: We designed a prospective phas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to ErbB Receptors

Share to Multivariate Analysis

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Open in PubMed

Identifiers

PMID: 22425916
DOI: 10.1097/JTO.0b013e31824a8bde

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22425916-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.PMID 22425916Read ↗

Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.Semantic proximity Read ↗

Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma.Semantic proximity Read ↗

Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.Semantic proximity Read ↗

[Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma].Semantic proximity Read ↗

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.Semantic proximity Read ↗

Pharmacotherapy targeting the EGFR oncogene in NSCLC.Semantic proximity Read ↗

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.Semantic proximity Read ↗

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.